#SXTP hashtag - Bluesky

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract 60 Degrees Pharmaceuticals (NASDAQ: SXTP) submitted a New Dietary Ingredient Notification (NDIN) to the FDA on March 11, 2026, for an Australian Chestnut Extract product; FDA review runs through May 25, 2026.The company also signed an option to license Florida State University capsule formulation methods and previously exercised a January 2026 license option for large-scale purification rights for castanospermine.

2 weeks ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

www.stocktitan.net/news/SXTP/60-degrees-pha...

1 0 1 0

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial 60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that all three patients in its expanded‑use trial of tafenoquine for relapsing babesiosis in immunosuppressed patients achieved cure after completing the regimen.The open‑label study used weekly tafenoquine added to atovaquone‑containing combinations sustained until two consecutive negative PCRs; combined data with a 2024 Yale report suggest near 100% cure in seven patients. Tafenoquine is not FDA‑approved for babesiosis and is approved in the U.S. for malaria prophylaxis as ARAKODA.

3 weeks ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

2 months ago

Breaking News: ( NASDAQ: #SXTP ) 60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use

0 0 0 0

@stockmaster70.bsky.social

2 months ago

Just In: ( NASDAQ: #SXTP ) 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA for Malaria Prevention

0 0 0 0

Stock Master

2 months ago

📢 Stocks Trending NOW: #GE #AMD #MRNA #PG #FCX #INTC #ABT #SXTP #META #ASTS

0 0 0 0

60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international

2 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock

2 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a planned expansion of sales and marketing for ARAKODA after a 6-month commercial pilot showed increasing product sales among prescribers. Plans for 2026 include doubling inside sales representatives, a new GoodRx partnership to broaden point-of-sale visibility, and an enhanced digital "surround sound" marketing campaign to boost prescriber awareness and engagement.Separately, the company will add at least two babesiosis clinical sites for ongoing randomized and expanded-access studies following FDA feedback on its Breakthrough Therapy designation request; FDA declined the request but acknowledged babesiosis as serious and suggested resubmission with controlled-trial data. Tafenoquine (ARAKODA) remains approved for malaria prophylaxis and is not approved for babesiosis treatment.

3 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine 90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing

4 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on

4 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study 60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that the first patient completing its expanded access study of ARAKODA® (tafenoquine) for relapsing babesiosis tested negative for Babesia by both a Mayo Clinic RT-PCR and an FDA-licensed RNA amplification assay that is described as at least 100x more sensitive than standard RT-PCR.On October 3, 2025 the company submitted a Breakthrough Therapy request to FDA and plans a Type B meeting in early 2026 to discuss requirements for a supplementary NDA; remaining patients are expected to finish between January and October 2026 and clinical data are expected in second half of 2026.

5 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning name B-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months

5 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

Vector-borne Disease Biotech 60 Degrees Pharmaceuticals Sets New Time for H.C. Wainwright Conference 60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Dr. Geoff Dow to present at H.C. Wainwright Global Investment Conference on Sept 9, 3:30 PM ET. One-on-one meetings available.

7 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results 60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2025 financial results, highlighting a 19% year-over-year decline in net product revenues to $101,000 due to a temporary supply chain disruption. Despite lower revenues, the company achieved increased profitability with a gross profit of $51,000, up from $35,000 in Q2 2024.Operating expenses decreased significantly to $1.86 million from $4.22 million in Q2 2024. The net loss improved to $1.84 million ($1.25 per share) compared to $4.29 million ($21.12 per share) in Q2 2024. With $1.97 million cash on hand and recent public offering proceeds of $4.46 million, the company projects runway through March 31, 2026.Research studies indicate the total addressable U.S. market for ARAKODA for human babesiosis could reach $1.1 billion over the remaining 10-year patent life, with annual babesiosis incidence estimated between 25,000-380,000 cases.

7 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

Major Breakthrough: Anti-Malaria Drug Tafenoquine Being Tested for Lyme Disease Treatment New research explores tafenoquine's potential against tick-borne illnesses. Tulane University partnership targets Lyme disease and Bartonella bacteria. See latest findings.

8 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering 60 Degrees Pharmaceuticals (NASDAQ:SXTP) has announced the pricing of a $5 million public offering with potential additional proceeds of up to $5 million through warrant exercises. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) at $1.90 per share, along with Series A-1 and A-2 warrants.The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. H.C. Wainwright & Co. is serving as the exclusive placement agent, with closing expected around July 16, 2025. The company plans to use proceeds for working capital and general corporate purposes.

8 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Mon Jul 14th - #TANH #SXTP #SINT #MSW #ZTEK #TCRT #RYET #PHVS #MOVE #ISPO #HTOO #AIFF #CNF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced plans to submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. The submission will be supported by three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, including one company-sponsored study at North Carolina State University.The studies demonstrated that tafenoquine was well-tolerated and effective in treating both experimental and naturally acquired Babesia infections in dogs. This development is significant as there are currently no FDA-approved oral treatments for canine babesiosis, an emerging tick-borne illness that affects hundreds to thousands of dogs annually in the United States.

8 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Jun 4th - #SXTP #TCMD #SBGI #POWW #OCG #MBRX #LOOP #KGEI #HIFS #GALT #FHTX #CCRN #BTMD #PCG #HTH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Only FDA-Approved Weekly Malaria Prevention Drug Now Available in Travel-Friendly 8-Count Package New ARAKODA 8-count format offers convenient malaria protection for shorter trips. Now available through major pharmacies including Amazon. See dosing details.

9 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results 60 Degrees Pharmaceuticals (NASDAQ: SXTP) has reported its Q1 2025 financial results, showing mixed performance. The company's net product revenues increased 55% year-over-year to $163.6 thousand, primarily driven by domestic sales of ARAKODA®. Gross profit saw significant growth of 124%, reaching $90.3 thousand compared to $40.2 thousand in Q1 2024.However, operating expenses rose to $2.09 million from $1.41 million in the previous year, with $535.4 thousand attributed to increased sales, investor-related services, and stock-based compensation. The company reported a net loss of $2.01 million ($1.56 per share) in Q1 2025, compared to a net income of $308.7 thousand ($1.83 per share) in Q1 2024, largely due to a $1.74 million change in fair value of derivative liabilities.

10 months ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Geoff Dow will participate in the Healing Lyme Summit from April 15-21, 2025, to discuss babesiosis, a tick-borne disease commonly occurring alongside Lyme disease. Dr. Dow will address the increasing prevalence of babesiosis in the United States, clinical challenges, and the need for better diagnostic and treatment options.The company is currently conducting two clinical trials (NCT06207370 and NCT06478641) evaluating tafenoquine for treating severe babesiosis and persistent disease in immunosuppressed patients. The summit is a free virtual event featuring scientific discussions and educational content on tick-borne illnesses.

11 months ago

#SXTP #SXTPW Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

www.stocktitan.net/news/SXTP/geoff-dow-ph-d...

0 0 0 0

11 months ago

BREAKING NEWS: ( NASDAQ: #SXTP ) Sixty Degrees Pharmaceuticals Inks Patent License Deal with Yale to Push Tafenoquine for Babesiosis Treatment and Prevention

0 0 0 0

11 months ago

NEWS: ( NASDAQ: #SXTP ) Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

0 0 0 0

140% Revenue Surge: 60 Degrees Pharma Expands Drug Access After FDA Approval Revenue jumps 140% as FDA approves Kodatef import. Babesiosis trials advance with interim data expected Q1 2026. Full analysis of expanded clinical programs inside.

1 year ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals Announces 2024 Annual Results

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0

Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? 1-for-5 reverse split aims to meet $1 minimum bid requirement. Shareholders' ownership percentage remains unchanged with automatic conversion process.

1 year ago

#SXTP #SXTPW 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

www.stocktitan.net/news/SXTP/60-degrees-pha...

0 0 0 0